Advertisement

Impact of Biotechnology in the Diagnostic and Therapeutic Management of Cardiovascular Disorders

  • Jawed Fareed
  • Debra Hoppensteadt
  • Lalitha Iyer
  • Michael Koza
  • Jeanine M. Walenga
  • Edward BermesJr.
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 369)

Abstract

Biotechnology has already exerted a major impact in the management of cardiovascular disorders by providing such drugs as tissue plasminogen activator (t-PA), urokinase, platelet targeting antibodies, recombinant anticoagulant agents such as hirudin and various modulatory proteins. On the diagnostic front, biotechnology has provided newer, more sensitive methods to detect minute changes in blood for the proper diagnosis and management of cardiovascular disorders. Several major breakthroughs in both the diagnosis and treatment of cardiovascular disorders have recently occurred. The measurement of troponin T and I in circulating blood provides a reliable measure of myocardial damage. Other analytes have also been identified for the rapid diagnosis of cardiovascular disorders. Such agents as tissue factor pathway inhibitor (TFPI), protein and antithrombin III have been developed and may prove to be useful in the management of antithrombotic disorders. Although the use of transgenic animals is still at experimental stages, the initial findings are promising and will provide important leads into the development of therapeutic proteins. Through biotechnology, recombinant inhibitors of fibrinolysis have also been developed and may be useful in the management of bleeding disorders. Nucleic acid derived drugs have been used for sometime. Several newer nucleic acid derivatives have been recently developed. An important consideration in the use of biotechnology derived drugs is the availability of a US Pharmacopoeial monograph on specific drugs. The subject of providing a monograph on biotechnology derived drugs is now being dealt with by the USP. Several other considerations in the development, clinical applications and the results of clinical trials on new biotechnology derived drugs are being addressed at this time. It is hoped that the impact of biotechnology on the diagnosis and treatment of cardiovascular disorders will result in a significant change in the management of these disorders.

Keywords

Tissue Factor Cardiovascular Disorder Fibrin Clot Tissue Factor Pathway Inhibitor Specific Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams, J.E., Bodor, G.S., Davila-Roman, V.G., Delmex, J.A., Apple, F.S., Hadenson, J.H. and Jaffe, A.S., 1993, Cardiac Troponin I — A marker with high specificity for cardiac injury, Circulation 88:101–106.CrossRefGoogle Scholar
  2. Bauer, K.A. and Rosenberg, R.D., 1987. The pathophysiology of the prothrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 70:343–350.Google Scholar
  3. Broze, G., Warren, J. and Novotnym L.A., 1988. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factors Xa: Insight into its possible mechanism of action, Blood 71:335–343.Google Scholar
  4. Farced, J., 1981, New methods in hemostatic testing. 1981, Perspectives in hemostasis. in “Perspectives in Hemostasis”. J. Fareed, ed., Pergamon Press, New York. NY.Google Scholar
  5. Fareed, J., Walenga, J.M. and Breddin, K., 1989. Newer avenues in antithrombotic therapy, Semin. Thromb. Hcmost. 15.Google Scholar
  6. Fareed, J., Walenga, J.M. and Hoppensteadt, D.A., 1988. Pharmacologic profiling of defibrotide in experimental models. Semin., Thromb. Hemost. 14:27–37.Google Scholar
  7. Fareed, J., Walenga, J.M. and Iyer, L. 1991. An objective perspective on recombinant hirudin: A new anticoagulant and antithrombotic agent. Blood Coag. Fibrinoly 2:135–148.CrossRefGoogle Scholar
  8. Fareed, J., Hoppensteadt, D., Walenga J.M. and Pifarre, R., 1993. New antithrombotic drugs for myocardial infarction in “Anticoagulation, Hemostasis and Blood Preservation in Cardiovascular Surgery”, R. Pifarre. ed., Hanley & Belfus. Philadelphia.Google Scholar
  9. Fareed, J., 1993a, Recombinant antithrombotic drugs. Impact on the management of thrombotic disorders in the 1990s. Proceedings in the International Biotechnology Exposition and Scientific Conference 1993), San Francisco. CA. pp. 50. 51. Cartlidge Associates. Belmont, CA.Google Scholar
  10. Fareed, J., Hoppensteadt, D., Walenga, J.M. and Bick, R.L., 1994, Current trends in the development of anticoagulant and antithrombotic drugs, Med. Clin. No. America 78:713–731.Google Scholar
  11. Fareed, J., 1994a, Proceedings of the International Biotechnology Exposition and Scientific Conference (IBEX 1994), San Francisco. CA. PP. 44. 46. 49. 50. 55. 67, Cartlidge Associates, Belmont, CA.Google Scholar
  12. Faxon, D.P., Sanborn, T.A. and Haudenschild, C.C., 1984, Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am. J. Cardiol. 53:72C–76C.CrossRefGoogle Scholar
  13. Hake, U., Schmid, F.X., Iversen, S., Dahm, M., Mayer, E., Hafner, G. and Oelert, H., 1993, Troponin T — a reliable marker of perioperative myocardial infarction? Eur. J. Cardiothorac. Surg. 7:628–633.CrossRefGoogle Scholar
  14. Piascik, M.M., 1991. Research and development of drugs and biologic entities. Am. J. Hosp. Pharm. 48(10):S 4–13.Google Scholar
  15. Sidoli, A., Galliani, S. and Baralle, F.E., 1990. DNA based diagnostic tests: Recombinant DNA and cardiovascular disease risk factors. Br. Med. Bulletin 46(4):941–959.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Jawed Fareed
    • 1
  • Debra Hoppensteadt
    • 1
  • Lalitha Iyer
    • 1
  • Michael Koza
    • 1
  • Jeanine M. Walenga
    • 1
  • Edward BermesJr.
    • 1
  1. 1.Departments of Pathology and PharmacologyLoyola University Medical CenterMaywoodUSA

Personalised recommendations